This article is more than 5 years old. Information may no longer be current.
Inotek completes milestone for glaucoma eye drop candidate
Click Here to Manage Email Alerts
LEXINGTON, Mass. — Inotek Pharmaceuticals announced that it has successfully completed the first two of three stages of a clinical trial for INO-8875, an eye drop candidate the company is developing for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.
The phase 2b trial is a multi-dose, randomized, double-masked, placebo-controlled, dose-ranging study designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of INO-8875. It is being conducted at multiple centers in the U.S., according to the release.
In response, Inotek’s investors have committed the final installment of their funding round, as well as an additional $3.7 million to expand the subject pool and duration of treatment in the final trial phase, the release said.